Peer Reviewed Research
2016
Yang B, Foley S, Toozs-Hobson P. Urinary tract infections: current and new preventative options.SM Journal of Clinical Medicine 2026;2(1):1018.
An early comprehensive review of non-antibiotic preventative strategies for recurrent UTI, identifying immunomodulation as the next clinical milestone.2017
Yang B, Foley S. Using Uromune as a novel treatment in women with recurrent UTIs.Journal of Clinical Urology 2017;10(2):47.
Baseline UK data on the initial cohort treated with a 3-month sublingual vaccine course - the start of the UK clinical vaccine framework.Yang B, Foley S. First experience in the UK with novel sublingual vaccine Uromune®.International Journal of Surgery 2017;47:S3-S4; and European Urology Supplements 2017;16(3):e233-e234. (conference abstracts)
Yang B, Foley S. Using FemTouch™ in the treatment of women with recurrent UTIs: first UK experience.AUA Annual Meeting (J Urol 2017;197(4S):e299). (conference abstract)
2018
Yang B, Foley S. First experience in the UK of treating women with recurrent UTIs with the bacterial vaccine Uromune®.BJUU International 2-18;121(2):289-292.
The landmark UK paper introducing sublingual polybacterial immunomodulation to British urology as an alternative to long-term antibiotic prophylaxis.Duffield E, Yang B, Foley S. The burning issue of urinary tract infectionsUrology News 2018;22(6).
A clinical review on primary-care diagnostic stewardship and the limits of dipstick testing in older and catheterised patients.2019
Duffield E, Yang B, Foley S. Urinary tract infection vaccines — the 'burning' issue.BJU International 2019;123(5):743–744.
A widely cited editorial reframing recurrent UTI care away from antibiotic dependency towards immunoprophylaxis.2020
Yang B, Foley S (Eds.). Female Urinary Tract Infections in Clinical PracticeSpringer Nature, 2020. ISBN 978-3-030-27908-0.
The definitive practical reference, with chapters on pathophysiology, diagnosis, lifestyle, methenamine, oestrogen and intravesical GAG-layer therapies.2021
Lorenzo-Gómez MF, Foley S, Nickel JC, … Yang B, et al. MV140 Phase III RCT — early efficacy, safety and healthcareNeurourology & Urodynamics, European Urology and the Journal of Clinical Urology.
(conference abstracts; 240 women across Spanish & UK sites)2022
Lorenzo-Gómez MF, Foley S, Nickel JC, Padilla-Fernández BY, González-Casado I, Martínez-Huélamo M, Yang B, Blick C, et al. Sublingual MV140 for prevention of recurrent urinary tract infections.NEJM Evidence 2022;1(5):EVIDoa2100018.
The definitive international, multicentre, double-blind, placebo-controlled Phase III trial — regulatory-grade evidence that a 3-month MV140 course safely prevents recurrent UTI.2024
Kanabar S, Foley SJ, Yang B. Safety and effectiveness of Uromune®: a 9-year long-term follow-up of the initial UK cohort.AUA Annual Meeting (J Urol 2024;211(5S):e1291–e1292).
The first long-term real-world follow-up, demonstrating durable, multi-year protection without long-term adverse events.Nickel JC, Foley S, Yang B, et al. Reducing recurrent UTIs in women impacts personal burden of disease: secondary analyses of a randomised placebo-controlled study.European Urology Open Science 2024.
Patient-reported outcomes showing reduced symptom burden, fewer antibiotics and improved quality of life.2025
Kanabar S, Foley SJ, Yang B. Impact of MV140 on healthcare costs in recurrent UTI: a 24-month real-world analysisICS-EUS Meeting, Abu Dhabi 2025 (Abstract #119)
(conference abstract)Musabyimana C, … Yang B. Evaluating Lodestar Dx as a rapid point-of-care alternative to standard MC&S in urological outpatients.EAU Conference Proceedings 2025
A 35-minute DNA-LAMP point-of-care test accurately identifying biofilm-hidden uropathogens missed by 48-hour culture.2026
Kanabar S, Foley SJ, Yang B. Effectiveness of double-dose MV140 in recurrent UTI secondary to neuropathic bladderAUA Annual Meeting (Abstract IP48-27)
Musabyimana C, … Yang B. Lodestar Dx as a rapid diagnostic alternative to culture and dipstick for pre-operative screening & outpatient stewardshipAUA Annual Meeting (Abstracts IP48-21, IP48-22)
Yang B, et al. (Eds.). Urinary Tract Infections in Clinical Practice (2nd ed.)Springer Nature, 2026
Yang B. Translational engineering of ultrasound-targeted microbubble destruction (UTMD) in the disruption of urological device biofilmsUniversity of Oxford research
Join the Gold Standard
If your clinic delivers structured, evidence-led recurrent UTI care, we invite you to formalise that expertise through accreditation.